Burger King Tests New Menu as 11% of U.S. Adults Use GLP-1 Drugs
Updated
Updated · NBC News · Jul 19
Burger King Tests New Menu as 11% of U.S. Adults Use GLP-1 Drugs
2 articles · Updated · NBC News · Jul 19
Summary
Whopper Bites and protein-forward bowls are being tested by Burger King as it prepares for customers who still want fast food but in smaller, higher-protein portions.
11% of U.S. adults now use a GLP-1 drug, according to Gallup, and nearly half of users told the National Restaurant Association they have cut back on dining out.
72% of 300 GLP-1 users surveyed by William Blair said they were specifically eating fewer hamburgers, reinforcing Burger King's push to adapt before any sales hit appears.
Burger King says the shift has not yet hurt business—strong Whopper demand continues and U.S. comparable sales rose 5.8% in the first quarter after a 1.1% decline a year earlier.
JPMorgan estimated in February that GLP-1 adoption could wipe out $30 billion to $55 billion in annual food-and-beverage revenue by 2030, making the drugs a broader industry threat.
As weight-loss drugs rewire American appetites, can fast food truly pivot from indulgence to nourishment?
With drugs now matching bariatric surgery, is the food industry facing permanent disruption or its greatest innovation challenge?
Fast Food in the Age of GLP-1: Burger King’s Strategic Response to a 21% Drop in Calorie Consumption
Overview
The fast-food industry is undergoing a major shift as consumer preferences evolve and more people use GLP-1 medications, which reduce appetite and portion sizes. Burger King has responded by introducing GLP-1 Friendly Choices, offering smaller, protein-rich, and easier-to-digest menu options. This strategy helps customers feel satisfied with less food and supports muscle mass, which is important for those on appetite-suppressing medications who risk losing lean body mass. By adapting its menu and operations, Burger King is positioning itself to meet new demands in a changing market.